Management of Persistent AFB Positive TB on Rifampicin-Based Therapy

Evaluation of Treatment Failure

Treatment failure is defined as continued or recurrently positive cultures after 3 months of appropriate multidrug therapy, with patients who remain culture-positive after 4 months definitively considered treatment failures 1
Possible causes of persistent AFB positivity include nonadherence to the prescribed regimen, unrecognized drug resistance, malabsorption of medications, and laboratory error 2

For patients with persistent AFB positive tuberculosis despite rifampicin-based therapy, treatment failure should be presumed, and a new regimen with at least three effective drugs should be initiated after collecting specimens for culture and drug susceptibility testing, as recommended by the American Thoracic Society 1, 2
Collect sputum specimens for AFB smear, culture, and drug susceptibility testing (DST) for both first-line and second-line drugs before changing therapy 1, 2
If the patient is seriously ill or has positive sputum AFB smears, start an empirical retreatment regimen immediately without waiting for DST results, according to the American College of Chest Physicians 1, 2
Never add a single drug to a failing regimen as this leads to acquired resistance to the added drug, as stated by the Infectious Diseases Society of America 1, 2, 3

An empirical regimen for patients with treatment failure on rifampicin-based therapy might include a fluoroquinolone, an injectable agent, and additional oral agents such as p-aminosalicylic acid (PAS), cycloserine, or ethionamide, as suggested by the Centers for Disease Control and Prevention 1, 2

Adjust the regimen based on drug susceptibility test results when available, as recommended by the World Health Organization 1, 2
Monitor sputum cultures monthly until two consecutive specimens are AFB smear- and culture-negative, according to the Centers for Disease Control and Prevention 4
Perform drug susceptibility testing if cultures remain positive after 2 months of the new regimen, as stated by the European Centre for Disease Prevention and Control 4
Monitor for adverse effects of second-line drugs, which are more frequent and severe than first-line drugs, as reported by the European Respiratory Society 5

For multidrug-resistant TB (MDR-TB, resistant to at least isoniazid and rifampicin), consult with or refer to a specialized TB treatment center, as recommended by the American Thoracic Society 1, 2

Failing to collect specimens for culture and DST before changing therapy, as warned by the Infectious Diseases Society of America 1
Adding only one new drug to a failing regimen, which leads to acquired resistance to the added drug, as stated by the Centers for Disease Control and Prevention 1, 2, 3
Delaying treatment modification in seriously ill patients while waiting for DST results, as cautioned by the American College of Chest Physicians 1, 2
Not considering the possibility of nonadherence, malabsorption, or laboratory error, as noted by the World Health Organization 2
Failing to consult with TB experts for complex drug-resistant cases, as recommended by the European Respiratory Society 1, 2